XSHE
300086
Market cap364mUSD
Oct 09, Last price
5.49CNY
1D
2.43%
1Q
-12.16%
Jan 2017
-60.56%
IPO
-60.34%
Name
Honz Pharmaceutical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Honz Pharmaceutical Co., Ltd. is a Chinese enterprise based in Guangzhou, primarily engaged in the creation, production, and commercialization of pharmaceutical drugs. While specializing in pediatric medications, the company also provides treatments for adults across a broad spectrum of health concerns. Its product offerings address conditions such as allergic responses, digestive and diarrheal issues, respiratory problems like coughs and flu, fevers, various infections, fungal ailments, pain relief, and endocrine disorders. Honz Pharmaceutical distributes its products to the market via an extensive network of agents and numerous retail sales outlets. The company officially adopted its current name in November 2016, having previously operated as HaiNan Honz Pharmaceutical Co.,Ltd.
Key people
Jiangyou Hong
Chairman of the Board, President · since 2025
Jing Li
Chief Financial Officer · since 2025
Liping Hong
Vice Chairman of the Board, Vice President · since 2019
Dexin Lin
Vice President, Secretary of the Board · since 2012
Hongchang Gao
Staff Elected Director · since 2025
Zhihui Hong
Director · since 2025
Youquan Li
Director · since 2019
Canhui Fang
Independent Director · since 2025
Linyan Tang
Independent Director · since 2025
Qinghe Wu
Independent Director · since 2022
Huanxue Zheng
Independent Director · since 2022
Headquarters & legal address
海南省海口国家高新技术产业开发区药谷工业园药谷三路6号
海口市, HI 570200
CN
海口市, HI 570200
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||